Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level

Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism

Milton Packer

Summary: SGLT2 inhibitors reduce heart failure events by directly acting on the failing heart, independent of renal tubular function. They restore cellular homeostasis through mechanisms such as promoting cytoprotective actions, increasing ATP synthesis, and inhibiting the accumulation of toxic metabolic by-products. These inhibitors also enhance autophagic flux, leading to the clearance of harmful substances and mitochondrial renewal.

NATURE REVIEWS CARDIOLOGY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c

Rahul Aggarwal et al.

Summary: This study assessed the efficacy of Sotagliflozin on heart failure clinical outcomes in individuals with different baseline glycosylated hemoglobin levels. The results showed that Sotagliflozin reduced heart failure outcomes, regardless of baseline HbA1c.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

添加到收藏夹

Review Medical Laboratory Technology

Cardiovascular benefit of SGLT2 inhibitors

Reza Mohebi et al.

Summary: SGLT2 inhibitors have been shown to significantly reduce cardiovascular risk in patients with T2D and also have a positive impact on heart failure. However, the exact mechanisms behind their cardiorenal benefits are still not fully understood.

CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2022)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Urology & Nephrology